PriceTargets.com logo

Marinus Pharmaceuticals - MRNS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.17
  • Forecasted Upside: 376.54 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$6.75 As of 10/3/2022 01:00 AM ET
▲ +0.1 (1.50%)

This chart shows the closing price for MRNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Marinus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNS

Analyst Price Target is $32.17
▲ +376.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Marinus Pharmaceuticals in the last 3 months. The average price target is $32.17, with a high forecast of $50.00 and a low forecast of $22.00. The average price target represents a 376.54% upside from the last price of $6.75.

This chart shows the closing price for MRNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Marinus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/9/2022JMP SecuritiesReiterated RatingBuy$22.00Medium
5/16/2022OppenheimerLower TargetNA$28.00N/A
4/20/2022Cantor FitzgeraldBoost Target$25.00 ➝ $28.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/22/2022HC WainwrightReiterated RatingBuy$38.00Medium
3/22/2022SVB LeerinkLower TargetOutperform$30.00 ➝ $27.00Medium
3/22/2022JMP SecuritiesBoost TargetMarket Outperform$21.00 ➝ $22.00Medium
3/22/2022Truist FinancialBoost TargetBuy$35.00 ➝ $50.00Medium
2/23/2022Truist FinancialLower Target$40.00 ➝ $35.00High
12/20/2021SVB LeerinkLower TargetOutperform$32.00 ➝ $30.00Low
12/7/2021JMP SecuritiesReiterated RatingBuy$23.00Low
10/18/2021SVB LeerinkReiterated RatingOutperformHigh
10/5/2021JMP SecuritiesReiterated RatingBuy$23.00Low
9/20/2021JMP SecuritiesReiterated RatingBuy$23.00High
8/30/2021JMP SecuritiesReiterated RatingBuy$23.00Medium
8/19/2021Robert W. BairdReiterated RatingBuy$32.00High
8/19/2021SVB LeerinkReiterated RatingBuyHigh
8/18/2021Truist FinancialBoost TargetBuy$35.00 ➝ $40.00High
8/17/2021Cantor FitzgeraldReiterated RatingOverweightHigh
5/20/2021Robert W. BairdReiterated RatingBuy$32.00Medium
3/10/2021HC WainwrightBoost TargetBuy$35.00 ➝ $38.00Medium
11/10/2020Cantor FitzgeraldBoost TargetOverweight$8.00 ➝ $27.00Low
9/30/2020Truist FinancialInitiated CoverageBuy$35.00High
9/28/2020HC WainwrightBoost TargetBuy$9.00 ➝ $35.00Low
9/25/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
9/25/2020JMP SecuritiesBoost TargetPositive ➝ Outperform$7.00 ➝ $26.00High
9/23/2020OppenheimerBoost TargetOutperform$7.00 ➝ $28.00N/A
9/15/2020JMP SecuritiesBoost Target$28.00 ➝ $16.00Low
9/15/2020OppenheimerBoost TargetPositive ➝ Outperform$24.00 ➝ $28.00High
9/15/2020SVB LeerinkBoost TargetOutperform$24.00 ➝ $32.00High
9/15/2020HC WainwrightReiterated RatingBuy$36.00High
9/15/2020Cantor FitzgeraldBoost TargetOverweight$24.00 ➝ $32.00High
9/15/2020Jefferies Financial GroupBoost TargetBuy$16.00 ➝ $24.00High
9/8/2020OppenheimerReiterated RatingBuy$24.00Low
8/7/2020OppenheimerReiterated RatingBuy$24.00Medium
8/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00Medium
7/1/2020CowenInitiated CoverageOutperformMedium
6/30/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $36.00High
5/5/2020Cantor FitzgeraldLower TargetOverweight$28.00 ➝ $24.00High
5/5/2020HC WainwrightReiterated RatingBuy$24.00High
4/9/2020Craig HallumInitiated CoverageBuy$18.00High
4/1/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
1/10/2020HC WainwrightBoost TargetBuy$20.00 ➝ $24.00Medium
12/19/2019OppenheimerInitiated CoverageOutperform$24.00High
11/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
11/13/2019HC WainwrightReiterated RatingBuy$20.00Low
10/18/2019HC WainwrightSet TargetBuy$20.00N/A
10/18/2019Cantor FitzgeraldReiterated RatingOverweight$28.00Medium
9/26/2019LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
9/3/2019HC WainwrightInitiated CoverageBuy$20.00High
8/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$12.00Low
7/25/2019LADENBURG THALM/SH SHReiterated RatingBuy$12.00High
7/23/2019MizuhoLower TargetNeutral$20.00 ➝ $6.80N/A
5/1/2019Cantor FitzgeraldReiterated RatingBuy$88.00High
5/1/2019LADENBURG THALM/SH SHReiterated RatingBuy$98.00High
3/5/2019Jefferies Financial GroupInitiated CoverageBuy$14.00 ➝ $40.00High
2/27/2019MizuhoDowngradeBuy ➝ Neutral$52.00 ➝ $20.00High
2/6/2019SVB LeerinkReiterated RatingOutperformHigh
12/26/2018Cantor FitzgeraldSet TargetBuy$88.00High
12/11/2018LADENBURG THALM/SH SHSet TargetBuy$88.00High
12/11/2018MizuhoReiterated RatingBuy$52.00Low
12/10/2018JMP SecuritiesBoost Target$116.00High
12/10/2018Cantor FitzgeraldSet TargetBuy$100.00High
12/4/2018Cantor FitzgeraldSet TargetBuy$76.00High
10/31/2018Cantor FitzgeraldSet TargetBuy$76.00Medium
9/25/2018MizuhoReiterated RatingBuy$52.00Medium
9/25/2018Cantor FitzgeraldSet TargetBuy$76.00High
9/17/2018Cantor FitzgeraldReiterated RatingBuy$76.00High
8/8/2018Cantor FitzgeraldSet TargetBuy$76.00Medium
8/2/2018MizuhoReiterated RatingBuy$52.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$76.00High
7/2/2018Cantor FitzgeraldInitiated CoverageOverweight$76.00High
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$80.00High
5/23/2018Robert W. BairdInitiated CoverageOutperform$60.00High
4/19/2018MizuhoReiterated RatingBuy$52.00Low
3/19/2018MizuhoInitiated CoverageBuy ➝ Buy$52.00High
2/15/2018HC WainwrightInitiated CoverageBuy ➝ Buy$132.00High
12/14/2017LaidlawInitiated CoverageBuy ➝ Buy$72.00High
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
3/7/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/6/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/4/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Marinus Pharmaceuticals logo
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $6.75
Low: $6.59
High: $6.86

50 Day Range

MA: $6.40
Low: $5.17
High: $7.51

52 Week Range

Now: $6.75
Low: $3.97
High: $13.15

Volume

78,097 shs

Average Volume

302,686 shs

Market Capitalization

$251.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Marinus Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Marinus Pharmaceuticals in the last year: Cantor Fitzgerald, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for MRNS.

What is the current price target for Marinus Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Marinus Pharmaceuticals in the last year. Their average twelve-month price target is $32.17, suggesting a possible upside of 376.5%. Truist Financial Co. has the highest price target set, predicting MRNS will reach $50.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $22.00 for Marinus Pharmaceuticals in the next year.
View the latest price targets for MRNS.

What is the current consensus analyst rating for Marinus Pharmaceuticals?

Marinus Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRNS will outperform the market and that investors should add to their positions of Marinus Pharmaceuticals.
View the latest ratings for MRNS.

What other companies compete with Marinus Pharmaceuticals?

Other companies that are similar to Marinus Pharmaceuticals include Selecta Biosciences, AC Immune, PepGen, Oramed Pharmaceuticals and Thorne HealthTech. Learn More about companies similar to Marinus Pharmaceuticals.

How do I contact Marinus Pharmaceuticals' investor relations team?

Marinus Pharmaceuticals' physical mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company's listed phone number is (484) 801-4670 and its investor relations email address is [email protected] The official website for Marinus Pharmaceuticals is www.marinuspharma.com. Learn More about contacing Marinus Pharmaceuticals investor relations.